ReviewPeptides2022
The renin-angiotensin system and cardiovascular autonomic control in aging.
Review in Peptides, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Revisiting renin-angiotensin-aldosterone system in aging: translational insights from bench to bedside and back.The Journal of clinical investigation · 2025Review
- Eight decades of follow-up link life course exposures to proteomic organ ageing and longevity.medRxiv : the preprint server for health sciences · 2025Article
- The angiotensin II type 2 receptor attenuates aging-associated arterial stiffness in female mice.American journal of physiology. Heart and circulatory physiology · 2025Article
- The heart-brain axis: neurocognitive frailty in heart failure.Journal of neurology · 2025Review
- Potential preventive effects of angiotensin-(1-7) on bone matrix quality in diabetic rats through modulation of the organic matrix.Joint diseases and related surgery · 2025Article
- Mineralocorticoid and estrogen receptors as sex-dependent modulators of vascular health in aging and obesity.The Journal of pharmacology and experimental therapeutics · 2025Review
- Review
- Review of Blood Pressure Control in Vulnerable Older Adults: The Role of Frailty and Sarcopenia.Journal of vascular diseases · 2025Article
- Lower Risk of Death and Kidney Failure Associated with Higher Target (vs Below-Target) Doses of RAS Inhibitors in Octogenarians with HFrEF.The American journal of medicine · 2025Article
- Article
- The role of mitofusin 2 in regulating endothelial cell senescence: Implications for vascular aging.iScience · 2024Article
- Microvascular angiotensin II type 2 receptor function is enhanced in young females and declines in a model of murine aging.The journal of cardiovascular aging · 2024Article
- Enhanced vasorin signaling mitigates adverse cardiovascular remodeling.Aging medicine (Milton (N.S.W)) · 2024Review
- The Senescent Heart-"Age Doth Wither Its Infinite Variety".International journal of molecular sciences · 2024Review
- Association between the Fatty Liver Index (FLI) and incident coronary heart disease: insights from a cohort study on the Chinese population.Frontiers in endocrinology · 2024Article
- Role of the autonomic nervous system in young, middle-aged, and older individuals with essential hypertension and sleep-related changes in neurocardiac regulation.Scientific reports · 2023Article
- Mechanisms of sex and gender differences in hypertension.Journal of human hypertension · 2023Review
- Article
- Hydrogen Sulfide Inhibited Sympathetic Activation in D-Galactose-Induced Aging Rats by Upregulating Klotho and Inhibiting Inflammation in the Paraventricular Nucleus.Biomedicines · 2023Article
- Control of aging by the renin-angiotensin system: a review ofFrontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Aging is the greatest independent risk factor for developing hypertension and cardiovascular-related diseases including systolic hypertension, vascular disease, ischemic events, arrhythmias, and heart failure. Age-related cardiovascular risk is associated with dysfunction of peripheral organ systems, such as the heart and vasculature, as well as an imbalance in the autonomic nervous system characterized by increased sympathetic and decreased parasympathetic neurotransmission. Given the increasing prevalence of aged individuals worldwide, it is critical to better understand mechanisms contributing to impaired cardiovascular autonomic control in this population. In this regard, the renin-angiotensin system has emerged as an important hormonal modulator of cardiovascular function in aging, in part through modulation of autonomic pathways controlling sympathetic and parasympathetic outflow to cardiovascular end organs. This review will summarize the role of the RAS in cardiovascular autonomic control during aging, with a focus on current knowledge of angiotensin II versus angiotensin-(1-7) pathways in both rodent models and humans, pharmacological treatment strategies targeting the renin-angiotensin system, and unanswered questions for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.